Drugs Home > Precautions and Warnings With Peginesatide
Although peginesatide may be helpful for many people, it may not be appropriate for those with a history of a heart attack, blood clot, or certain other medical issues. It is also important that your healthcare provider knows if you are pregnant or breastfeeding, as this drug may be unsafe in these circumstances. Other important precautions for using peginesatide safely include warnings of potential cardiovascular problems.
What Should I Tell My Healthcare Provider?You should talk with your healthcare provider prior to using peginesatide (Omontys®) if you have:
- High blood pressure (hypertension)
- Heart disease
- A history of a heart attack, blood clot, or stroke
- Congestive heart failure (CHF)
- Any allergies, including to foods, dyes, or preservatives.
- Pregnant or thinking of becoming pregnant
Specific Peginesatide Precautions and WarningsSome warnings and precautions to be aware of prior to receiving this medicine include the following:
- Peginesatide may increase the risk of serious cardiovascular problems, including heart attacks, strokes, congestive heart failure, and blood clots. This risk is higher if peginesatide increases your hemoglobin (a measure of red blood cells) too quickly or too much. Your healthcare provider should measure your hemoglobin frequently and adjust your peginesatide dosage to prevent this rapid or significant increase in hemoglobin levels.
However, this will not prevent all cardiovascular problems, and you and your healthcare provider must weigh the potential benefits and risks. Studies have not found a dosage, dosing strategy, or hemoglobin target level that does not increase the risks for cardiovascular problems.
- Peginesatide is approved only for use in people with chronic kidney disease who are on dialysis. Studies have shown that this medicine increased the risk for serious side effects when used in people who were not on dialysis.
- Peginesatide may accelerate the worsening of cancer and can shorten survival rates. This risk must be weighed against the potential benefits of using peginesatide. This drug is not recommended for use in people with cancer, unless the anemia is clearly caused by chronic kidney disease and not by the cancer or chemotherapy treatment.
- Peginesatide may cause high blood pressure (hypertension). This can be a problem, especially if you already have high blood pressure. Your healthcare provider should monitor your blood pressure closely while you are using peginesatide.
- In rare cases, people can form antibodies to peginesatide, causing severe anemia. If your anemia worsens while you are receiving this medication, your healthcare provider should check to see if you are forming these antibodies. In this situation, you may need to stop using peginesatide permanently.
- Peginesatide can cause problems with the dialysis access site (including clotting). Certain measures, such as an adjustment in anticoagulant dosage, might be necessary to avoid or treat such problems.
- Peginesatide is unlikely to react with other medications (see Drug Interactions With Peginesatide).
- Peginesatide is a pregnancy Category C medication. This means that it may not be safe for use during pregnancy. Talk to your healthcare provider about the risks and benefits of using the drug during pregnancy (see Omontys and Pregnancy).
- It is not known if peginesatide passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to receiving the drug (see Omontys and Breastfeeding).